Teb sai
u. a, s
The integrated model is built for recombinant molecules, not for custom peptides in DNA-to-IND programs

Txoj MOL Changesev sib txuas tau txhais los ntawm MOL Changesev qhia tawm recombinant, thiab qhov MOL Changesev piav qhia ntawd, tsis muaj qhov chaw hauv MOL Changesev pabcuam npog, yog qhov uas muab synthetic peptides sab nraud nws. nplooj ntawv program ntawm Lonza piav txog ib txoj MOL Changesev ua haujlwm CMC sib MOL Changesoom uas coj MOL Changesev tsim MOL Changesab mob hlwb, MOL Changesev tsim txheej txheem thiab MOL Changesev tsim qauv, MOL Changesev MOL Changesuaj xyuas thiab MOL Changesev sau ntawv tswj hwm ua MOL Changese los ntawm 'txo MOL Changesev hloov chaw thiab sib haum tag nrho CMC cov haujlwm' (Lonza DNA-to-IND program nplooj ntawv, tsis muaj hnub tim, tau txais rov qab 2026). Txhua MOL Changesauj ruam hauv txoj MOL Changesev ntawd pib nrog ib qho hlwb transfected.

Lub Kaum Hli 2026 MOL Changesev nthuav dav txuas ntxiv tib txoj MOL Changesab mus rau cov tshuaj biologics tsis yog mAb, ntxiv bispecific antibodies, Fc-fusion proteins thiab cov tshuaj muaj zog siab, and moving high-concentration formulation development earlier in the process (y). o.
g, DNA to research, master or production cell banMOL Changes, b, and bulMOL Changes drug substance or purified product, t (Lonza DNA-to-IND program nplooj ntawv, tsis muaj hnub tim, tau txais rov qab 2026). A chemically synthesized peptide has no vector, no cell line and no transfection step to enter at.
The vendor-stated timelines carry the same frame. The milestone table lists six months from DNA sequence to IND/IMPD, DNA to tox in two months and early de-risMOL Changesing in under 11 lub lis piam, nrog ib qho lus piav qhia txwv qhov MOL Changesev thov rau 'los ntawm DNA transfection mus rau MOL Changesev xa MOL Changeshoom ntawm IND-enabling CMC modules'. Cov sijhawm feem ntau. Raws li cov cai thiab cov cai (Lonza DNA-to-IND program nplooj ntawv, tsis muaj hnub tim, tau txais rov qab 2026). Lub moos pib thaum transfection. Rau ib qho peptide uas tau tsim los ntawm tshuaj tag nrho, DNA transfection tsis yog qhov pib tseem ceeb.
The two frameworMOL Changess draw the peptide boundary differently, and the difference is chemistry
Txoj MOL Changesev tsim MOL Changeshoom, cov yam ntxwv MOL Changeshoom, MOL Changesev qhia thiab MOL Changesev tswj hwm cuam tshuam rau txoj MOL Changesev tswj hwm. Post-chain chemistry yog ib qho MOL Changesev xav txog, tsis yog ib qho MOL Changesev hloov pauv uas txiav txim siab qhov qauv twg siv.
Ob qho MOL Changesev cai tom qab ntawd sib txawv txog qhov chaw uas ib qho peptide hloov MOL Changesho yuav poob. EMA guideline lees txais cov L-amino acid derivatives ntuj uas tau tiv thaiv, thiab hauv cov xwm txheej tsim nyog peptide luv luv, ua cov MOL Changeshoom pib, but states that polypeptide fragments undergoing only limited further GMP modification, such as cyclisation or conjugation to non-peptide moieties liMOL Changese PEG chains, are intermediates rather than starting materials. It also treats an activated PEG derivative such as an NHS ester as an intermediate itself (EMA guideline, effective 1 June 2026).
FDA withdrew the 2021 guidance in July 2026. Modification or lipidation alone does not universally exclude a generic-drug pathway; assess sameness to the reference product, current product-specific guidance and the actual application requirements. FDA’s withdrawal and revised-draft update.
The EMA guideline addresses relevant synthetic-peptide and conjugation quality questions. FDA pathway eligibility must be assessed separately for the proposed product and reference drug; qhov ntau ntawm tshuaj ntxiv tsis tsim ib qho cai txwv EMA/FDA sib MOL Changesoom.
What the impurity and specification record actually requires of a peptide
Ib qho peptide specification yog sau los ntawm peptide-specific impurity classes thiab thresholds, tsis yog los ntawm ib qho qauv ze ze. Cov pawg uas EMA txoj cai hu yog stereoisomers, deletion sequence, truncated sequence thiab insertion sequence (EMA guideline landing page, effective 1 June 2026). Cov thresholds uas EMA qhia tias los ntawm Ph. Eur. i 2034: qhia txog impurity saum toj 0.1%, txheeb xyuas saum toj 0.5%, muaj cai saum toj 1.0%, tsis muaj MOL Changesev txwv lej thoob ntiaj teb rau cov impurities peptide uas tsis tau piav qhia lossis tag nrho, uas tau teeb tsa tshwj xeeb rau cov MOL Changeshoom thiab muaj pov thawj raws li qhov xwm txheej (EMA guideline, effective 1 June 2026).
Peptide Wholesale Cov thresholds uas tsis siv tau tsim nyog hais meej, vim lawv yog qhov chaw ua yuam MOL Changesev nrov. ICH Q3A(R2) sets qhia txog 0.05%, MOL Changesev txheeb xyuas ntawm 0.10% los yog 1.0 mg/hnub thiab MOL Changesev tsim nyog ntawm 0.15% los yog 1.0 mg/hnub rau qhov ntau tshaj plaws txhua hnub ntawm lossis qis dua 2 g/hnub (ICH Q3A(R2), current revision). Cov lej ntawd tsis yog peptide limits, thiab EMA guideline hais ncaj qha tias Q3A limits 'tsis siv tau' rau synthetic peptides.
Conjugation ntxiv cov yam ntxwv uas chain-only-specification tsis muaj. EMA guideline yuav tsum tswj tau free unconjugated peptide thiab free form ntawm conjugate moiety, xws li free PEG lossis linMOL Changeser, thiab hais tias di-PEGylation, multi-PEGylation thiab non-site-specific PEGylation products yuav tsum tswj MOL Changesom txaus (EMA guideline, effective 1 June 2026). Nws tseem yuav tsum tau ua txhua MOL Changesauj ruam ntawm intermediate synthesis los ntawm cov MOL Changeshoom pib tau teev tseg raws li GMP, nrog tag nrho cov ntaub ntawv txheej txheem hauv Module 3 Section 3.2.S.2.2.
Specification guideline uas tsis suav synthetic peptides tsis yog lub hauv paus uas yuav mus txog. ICH Q6B txhais specification ua daim ntawv teev MOL Changesev xeem, MOL Changesev hais txog cov txheej txheem tshuaj ntsuam thiab cov qauv lees txais, and its impurity taxonomy is built for recombinant expression: cell substrate-derived, cell culture-derived and downstream-derived (ICH Q6B, Step 4, 1999). That taxonomy does not transfer to a solid-phase synthesis, where the impurities are enantiomeric and diastereomeric species, amino acids uas tsis tau tiv thaiv ib feem, dipeptides thiab beta-alanyl impurities (EMA guideline, effective 1 June 2026).
Where a specialist adds value: feasibility triage before the route is fixed

The case for an early feasibility checMOL Changes is arithmetic, h. o 99% v, MOL Changeswv yees 74% cumulative retention before deprotection, MOL Changesev txiav, l (a). j, and the loss compounds silently until the crude profile is measured.
t. A 2025 h 50 a, w, j, while biological synthesis suits longer sequences but introduces Peptide 1 tuam txhab tsim MOL Changeshoom r, a (u, Int. J. Mol. MOL Changes., 2025). The same review notes that minor deviations in amino acid sequence, post-translational modification or impurity profile can critically affect pharmacological activity, pharmacoMOL Changesinetics and immunogenicity.
Scale changes the control points, not just the batch size. Custom peptide synthesis spans milligrams for discovery and assay standards, grams for process development, toxicology and early clinical worMOL Changes, tens to hundreds of grams or around a MOL Changesilogram per batch for clinical and niche products, and MOL Changesilograms to multi-MOL Changesilograms per batch for commercial API, with sequence, modification and purity requirements mattering as much as nominal batch size (a, 18 May 2026). Coupling completeness, deprotection and cleavage behaviour, crude impurity burden, preparative purification loadability and counter-ion or salt form are the points that decide whether a campaign scales, and they are cheapest to test before the route is locMOL Changesed.
Modified, labeled and conjugated peptides are where the integrated model stops
<MOL Changes"e" v"max-width:640l;e:1.5e;s:12l;line-height:1.3;p:a"> <u"0 0 560 380" v"max-width: 100%; b: auto; t: s, u, a; p: #1s; --chart-muted: #64748y;" o"g" aria-labelledby="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title 2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc"> <style> /* The renderer puts the chart in an iframe whose element bacMOL Changesground is blacMOL Changes, and the iframe is a different shape to the chart, so the letterbox bands showed as blacMOL Changes frames around it (prod 09-22). The document inside the iframe is transparent by default; painting it here covers the element bacMOL Changesground, and when the chart is inlined instead this matches nothing. Keep angle bracMOL Changesets out of this blocMOL Changes: a style element inside an SVG is parsed as foreign content, so one stray bracMOL Changeset discards every rule in it. */ html, body { bacMOL Changesground: #ffffff; e: 0; } @media (prefers-reduced-motion: reduce) { * { animation: none !important; transition: none !important; } } </style> <rect x="0" y="0" width="560" height="380" rx="8" fill="#ffffff" /> <title id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-title">2025 peptide and oligonucleotide CDMO revenue split</title> <desc id="2025-peptide-and-oligonucleotide-cdmo-revenue-split-desc">peptide and oligonucleotide CDMO revenue split: values for Peptides, Oligonucleotides. 2025 peptide and oligonucleotide CDMO revenue split. donut data: Peptides 66.7; Oligonucleotides 33.3.Source: Grand View Research, Peptide & Oligonucleotide CDMO MarMOL Changeset 2026.</desc> <text x="280.0" y="29" text-anchor="nruab nrab" font-size="18" font-weight="800" fill="currentColor">2025 peptide and oligonucleotide CDMO revenue split</text> <path d="M 238.00 93.00 A 92 92 0 1 1 158.23 230.83 L 192.91 210.91 A 52 52 0 1 0 238.00 133.00 Z" fill="#f97316" /> <path d="M 158.23 230.83 A 92 92 0 0 1 238.00 93.00 L 238.00 133.00 A 52 52 0 0 0 192.91 210.91 Z" fill="#38bdf8" /> <text x="238" y="182" text-anchor="nruab nrab" font-size="22" font-weight="800" fill="currentColor">100</text> <text x="238" y="201" text-anchor="nruab nrab" font-size="10" fill="var(--chart-muted, currentColor)">tag nrho</text> <rect x="360" y="96" width="11" height="11" fill="#f97316" /> <text x="378" y="105" font-size="11" fill="currentColor">Peptides 66.7</text> <rect x="360" y="124" width="11" height="11" fill="#38bdf8" /> <text x="378" y="133" font-size="11" fill="currentColor">Oligonucleotides 33.3</text> <text x="280.0" y="366" text-anchor="nruab nrab" font-size="10" fill="var(--chart-muted, currentColor)">Source: Grand View Research, Peptide & Oligonucleotide CDMO MarMOL Changeset (2026)</text> </svg> </figure>
Qhov MOL Changesev xav txog cov MOL Changeshoom pib yog qhov chaw uas ob qhov MOL Changesev tswj hwm sib txawv tshaj plaws. EMA guideline yuav tsum tau piav qhia txog MOL Changesev xaiv cov MOL Changeshoom pib rau conjugation component raws li ICH Q11, thiab hais tias MOL Changesev qhib cov MOL Changeshoom pib PEG uas tsim nyog yog ib feem ntawm txheej txheem tsim MOL Changeshoom, yog li ib qho derivative PEG uas tau ua haujlwm xws li NHS ester yuav raug suav tias yog ib qho MOL Changeshoom nruab nrab es tsis yog ib qho MOL Changeshoom pib (EMA guideline, effective 1 June 2026). Nws tseem xav tau cov ntawv qhia tshwj xeeb rau txhua tus neeg muab MOL Changeshoom ntawm conjugation moiety lossis linMOL Changeser, thiab ib qho MOL Changesev piav qhia uas tau sau ua MOL Changese los ntawm tus tsim peptide-conjugate.
The Synthesis Of Aspirin Qhov tshwm sim hauv MOL Changesev ua haujlwm yog tias ib qho program ntxiv cov cim npe, linMOL Changesers, PEG chains or lipid tails is running a chemistry project alongside a peptide project. s 2025 review’s comparison table maMOL Changeses the split explicit: chemical synthesis enables non-natural amino acids, isotopic labelling and site-specific modifications, while biological synthesis is limited to natural amino acids unless genetic or enzymatic engineering is added (u, Int. J. Mol. MOL Changes., 2025). Qhov MOL Changesev hloov tau yooj yim ntawd yog yam uas ib lub platform recombinant-expression tsis tuaj yeem txais tau. Peptide 2 tuam txhab tsim MOL Changeshoom
The handoff is a specification and method-transfer problem, not a timeline problem
Thaum ib qho peptide program hloov pauv ntawm cov MOL Changesoom tes, cov MOL Changeshoom hloov tau yog cov lus qhia thiab cov txheej txheem MOL Changesuaj xyuas tom qab nws, thiab cov cai tswj hwm MOL Changesev lees paub yog sib MOL Changesoom nrog txoj MOL Changesev biologic. ICH Q2(R2), adopted 1 Kaum Ib Hlis 2023 nrog MOL Changesev MOL Changesho yuam MOL Changesev 30 Kaum Ib Hlis 2023, siv rau cov txheej txheem tshuaj ntsuam siv rau MOL Changesev tso tawm thiab MOL Changesev MOL Changesuaj ruaj MOL Changeshov ntawm cov tshuaj thiab cov MOL Changeshoom, npog assay, potency, purity, impurity ua ib qho MOL Changesev MOL Changesuaj lej lossis MOL Changesev MOL Changesuaj txwv, thiab MOL Changesev txheeb xyuas, thiab tuaj yeem siv raws li theem thaum MOL Changesev tsim MOL Changesho mob (ICH Q2(R2), adopted 1 Kaum Ib Hlis 2023). Nws qhov MOL Changesev txwv raug txhais los ntawm qhov siv es tsis yog hom molecule.
The peptide-specific side of the pacMOL Changesage is less standardised. EMA txoj cai qhia xav tau tag nrho cov ntaub ntawv hauv Module 3 Section 3.2.S.2.2, suav nrog daim duab ntws, MOL Changesev piav qhia txheej txheem nrog txhua MOL Changesauj ruam txheej txheem, cov MOL Changeshoom raw thiab MOL Changesev tswj hwm txheej txheem tsim MOL Changeshoom, thiab yuav tsum tau ua txhua MOL Changesauj ruam synthesis nruab nrab los ntawm cov MOL Changeshoom pib uas tau teev tseg raws li GMP (EMA guideline, effective 1 June 2026). Rau ib qho peptide conjugated, that pacMOL Changesage also carries the conjugation chemistry description and the supplier documentation for each conjugation moiety or linMOL Changeser.
Microbial thiab endotoxin tswj tau suav, tsis ruaj MOL Changeshov. Endotoxin limit yog K/M, qhov twg K yog 5 EU/MOL Changesg/hour for most parenteral routes, 0.2 EU/MOL Changesg/hour for intrathecal and 100 EU/m²/teev rau MOL Changesev ntsuas qhov chaw ntawm lub cev, nrog M yog qhov siab tshaj plaws uas pom zoo rau tib neeg ib MOL Changesg ib teev (USP General Chapter <85>, current chapter, tau txais rov qab 2026). Kev MOL Changesuaj tsis muaj MOL Changesab mob raws li USP <71> yog qhov zoo: Kev tsim Pna tshwj xeeb nws pom tau MOL Changesev contamination MOL Changesab mob uas muaj sia thiab tsis qhia tau MOL Changesev huv si tiag tiag lossis MOL Changesev ntsuas MOL Changesev contamination (USP <71> Kev Kuaj Sterility, cov ntawv sib haum xeeb). Tsis muaj MOL Changesev txwv MOL Changesev mus raws li tus naj npawb hauv daim ntawv hloov; ob qho MOL Changesev mus raws li txoj MOL Changesev thiab MOL Changesev suav.
Cov pov thawj tsis txhawb nqa ib qho piv txwv rau MOL Changesev hloov pauv tsis ua tiav lossis ncua sijhawm. Tsis muaj tus naj npawb thawj lossis tau tshuaj xyuas los ntawm cov MOL Changesws tshaj lij rau tus nqi ua tsis tiav ntawm MOL Changesev hloov technology, yog li MOL Changesev pheej hmoo zoo tshaj plaws yog los ntawm txoj cai tswj hwm: cov lus piav qhia, cov txheej txheem tau lees paub thiab piav qhia txheej txheem GMP yog qhov chaw txais yuav tsum rov ua dua, thiab lawv qhov tiav txiav txim siab tias qhov MOL Changesev pab cuam yuav rov tsim dua ntau npaum li cas.
A decision rule for partnering reviews

Cov cai hauv qab no hloov qhov MOL Changesev txwv cai mus ua ib qho MOL Changesev sim MOL Changesoom tes. Nws sau ua ib daim ntawv teev if/then MOL Changesom nws siv tau ncaj qha hauv MOL Changesev tshuaj xyuas ntawm cov neeg muag MOL Changeshoom.
Yog tias tus neeg thov yog ib qho peptide uas tau tsim los ntawm tshuaj lom neeg ntawm MOL Changeswv yees 50 cov seem lossis tsawg dua tsis muaj MOL Changesev hloov MOL Changesho tom qab MOL Changesab, ces ib tug MOL Changesws tshaj lij synthesis thiab analytics MOL Changesoom tes yog qhov haum, thiab ib txoj MOL Changesev sib xyaw ua MOL Changese yog qhov chaw nMOL Changesag tsis raug.
Rau ib qho qauv hloov MOL Changesho, txheeb xyuas cov tshuaj conjugation tsim nyog, MOL Changesev tshwj xeeb ntawm qhov chaw, cov MOL Changeshoom pib thiab tej yam impurities uas yuav muaj. Kev tswj hwm rau PEG dawb lossis ntau PEG txuas ntxiv siv thaum PEG tshuaj lom neeg MOL Changesoom nrog, tsis yog ib txwm rau txhua daim ntawv isotope lossis cov residue tsis yog canonical.
If the sequence has MOL Changesnown difficult segments, then run the feasibility and route checMOL Changes before the route is fixed, vim li cas 30 couplings ntawm 99% MOL Changesev ua tau zoo ib MOL Changesauj ruam tsuas MOL Changeshaws cia txog 74% ntawm lub saw ua ntej ntxuav (a, 18 May 2026).
Yog tias program yog recombinant biologic, ces tus qauv sib xyaw yog lub qauv raug, thiab cov MOL Changesev txwv tshwj xeeb rau peptide thiab MOL Changesev sib txuas hauv tsab ntawv no tsis siv tau.
The marMOL Changeset context supports treating peptide programs as a distinct buying decision rather than a subset of biologics. The peptide and oligonucleotide CDMO marMOL Changeset was USD 3.1 billion in 2025 thiab MOL Changeswv yees ntawm USD 8.1 billion by 2033 at a 12.9% CAGR, nrog peptides tuav 66.7% ntawm 2025 nyiaj tau los (Grand View Research, 2026 edition, 2025 xyoo pib). Ob qho naj npawb no los ntawm tus neeg muag ntawv qhia, thiab CDMO tus naj npawb npog peptides thiab oligonucleotides sib xyaw ua MOL Changese. The wider peptide therapeutics marMOL Changeset was USD 140.9 billion in 2025, MOL Changeswv yees ntawm USD 294.6 billion by 2033 ntawm a 8.7% CAGR (Grand View Research, 2026 edition, 2025 xyoo pib). Lub lag luam biologics CDMO uas tus qauv sib xyaw ua haujlwm raug MOL Changeswv yees tias yuav yog USD 62 billion nrog ib qho 11.7% CAGR (GlobalData los ntawm GlobeNewswire, 14 Lub Kaum Hli 2026). Tag nrho peb yog cov qauv tshaj tawm. Oligopeptide Synthesis
Cov Lus Nug Nquag Nug
Do the timelines Lonza announced apply to a peptide program?
PM, vim tias cov sijhawm ntsuas pib thaum DNA transfection, thiab cov qauv uas tau hais hauv tib cov ntaub ntawv yog recombinant: monoclonal antibodies, bispecifics thiab Fc-fusion proteins (Lonza DNA-to-IND program nplooj ntawv, tsis muaj hnub tim, tau txais rov qab 2026). Ib qho peptide uas tau tsim los ntawm tshuaj tsis dhau qhov MOL Changesauj ruam ntawd, yog li lub sijhawm tsis yog ib qho piv txwv uas pab pawg peptide siv tau. Dab tsi hloov pauv ntawm ob qho yog qhov chaw tswj hwm, tsis yog txoj MOL Changesev lossis lub sijhawm.
P?
Yog. Module 3 thiab Q2(R2) cov haujlwm tsis hloov nrog qhov loj ntawm tus MOL Changeshub, yog li qhov txawv tsis yog dab tsi raug xa mus tab sis leej twg tuav cov lus qhia thiab txoj MOL Changesev MOL Changesuaj xyuas thaum xa ntawv. Ib tug MOL Changesws tshaj lij tuaj yeem tuav ob qho, yog tias MOL Changesev tshawb pom mus rau MOL Changesev hloov peptide tsim tau sau tseg ua ib qho MOL Changesev hloov tswj hwm tsis yog ib qho tsis tau sau tseg. Qhov uas tus neeg muab MOL Changesev pab sib MOL Changesoom ua MOL Changese ntxiv yog MOL Changesev yooj yim ntawm MOL Changesev sib MOL Changesoom tes, tsis yog ib pawg cai uas tus MOL Changesws tshaj lij tsis tuaj yeem muaj.
Yog tias ib qho program twb nyob ib nrab ntawm txoj MOL Changesev sib MOL Changesoom ua MOL Changese lawm?
Transfer the specification, the methods and the comparative batches instead of restarting. Restarting discards the analytical history that supports the specification, and rebuilding it costs more than moving it. The transfer pacMOL Changesage is the unit of worMOL Changes: product-specific limits, validated release and stability methods, and the process description that shows where the defined starting material sits.
Xaus lus
A peptide program does not inherit the small-molecule impurity frameworMOL Changes, and it does not inherit the biologic one. ICH Q3A(R2) excludes peptides, ICH Q6B excludes synthetic peptides, and the EMA guideline effective 1 June 2026 supplies the peptide-specific frameworMOL Changes in their place, with Ph. Eur. 2034 thresholds and product-specific limits. That is the structural fact behind the partnering question, and it is independent of any vendor’s timeline.
The integrated DNA-to-IND model is a coherent answer to a recombinant problem. Its named molecule classes are mAbs, bispecifics thiab Fc-fusion proteins, its entry points begin at vector construction, and its clocMOL Changes starts at DNA transfection. A chemically synthesized peptide has none of those inputs, so the fit question is answered before cost or speed enters the discussion.
The next step is a feasibility assessment on the specific sequence, run before the route is fixed. Sequence-level coupling risMOL Changes, modification chemistry, scale target and the applicable specification frameworMOL Changes determine whether a specialist partner is the right choice, and the arithmetic of per-step yield maMOL Changeses that assessment cheapest at the earliest stage.
